Tetrathiomolybdate (TM) is an orally active agent for treatment of disorders of copper metabolism. Here we describe how TM inhibits proteins that regulate copper physiology. Crystallographic results reveal that the surprising stability of the drug complex with the metallochaperone Atx1 arises from formation of a sulfurbridged copper-molybdenum cluster reminiscent of those found in molybdenum and iron sulfur proteins. Spectroscopic studies indicate that this cluster is stable in solution and corresponds to physiological clusters isolated from TM-treated Wilson's disease animal models. Finally, mechanistic studies show that the drug-metallochaperone inhibits metal transfer functions between copper trafficking proteins. The results are consistent with a model wherein TM can directly and reversibly downregulate copper delivery to secreted metalloenzymes and suggest that proteins involved in metal regulation might be fruitful drug targets.
Excess dietary molybdate (MoO 4 2-
) uptake was first linked to a fatal disorder in cattle known as 'teart' pastures syndrome (1) and later to a neurological disorder in sheep known as 'Swayback' (2) . Both disorders arise from Mo-induced copper deficiency and the symptoms are readily reversed with copper supplementation. While molybdate itself has little or no affinity for copper ions, the active copper-depleting agent, TM (MoS 4 2-), is formed in the ruminants digestive track and readily reacts with Cu I or Cu II to form insoluble compounds.
These zoogenic studies inspired the development of molybdenum compounds to treat copper-dependent diseases in humans (3). The potent chelating and antiangiogenic activities of orally-active formulation of TM, such as the ammonium salt [(NH 4 ) 2 (MoS 4 )] (4-6) and the choline salt (ATN-224) (7, 8) have been used in treatment of Wilson disease, where copper accumulation leads to hepatic and neurological disorders; as well as in the inhibition of metastatic cancer progression in a number of clinical trials (9) (10) (11) . TM inhibits several copper enzymes including ceruloplasmin (Cp), ascorbate oxidase, cytochrome oxidase, superoxide dismutase (SOD1), tyrosinase, and the Enterococcus hirae ATPase (CopB) (12, 13) , and also downregulates the expression of cytokines such as the vascular endothelial growth factor (VEGF), as well as transcription factors such as the nuclear factor-κB (NF-κB), involved in angiogenesis signaling pathways (14, 15) . While TM can bind to Cu-Cp (12), copper serum albumin (Cu-BSA) (16) and Cu-containing metallothioneins (Cu-MT) (17) , and has been proposed to inhibit SOD1 by partially removing copper from the enzyme (8, 18 ) the reaction chemistry and structures of these complexes have not been resolved. Metallochaperones constitute a particular kind of protein that delivers metal ions to specific cytoplasmatic targets in the cell (19) . The prototypical metallochaperone, yeast Atx1, transfers Cu I along a trafficking pathway via electrostatic interactions with structurally-homologous N-terminal domains of the ATPase, Ccc2 (20, 21) . Likewise, the closely related human copper metallochaperone, Atox1 can transfer copper to N-terminal domains of the copper-transporting ATPases 7a and 7b, also known as the Menkes and Wilson disease proteins. All three of these proteins are important in mammalian copper homeostasis and provide copper to secreted enzymes that are important in vascular integrity such as Cp and extracellular SOD (ecSOD). We anticipated that TM would readily remove Cu I from its binding site in Atx1
with subsequent formation of a typical polymeric CuMo sulfide precipitate. We found instead a robust TMmetallochaperone complex with metal sulfur ratios reminiscent of the FeMo cofactor-complex in nitrogenase (22) and elucidated how this antiangiogenic drug affects the structure and function of this canonical metal trafficking domain. Direct reaction of TM with Cu-Atx1 leads to rapid formation of an air stable purple complex that can be readily
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isolated by size exclusion chromatography (23) . Crystals of this complex diffract to 2.3 Å (fig. S1 ) and the X-ray structure reveals the presence of 12 Cu-Atx1 molecules in the asymmetric unit arranged as four TM-Cu-Atx1 noncrystallographic trimers ( fig. S2 ). The overall structure of each Atx1 monomer is similar to previously determined structures, retaining the 'ferredoxin-like'βαββαβ fold (24) , with two cysteines involved in copper binding (Cys15 and Cys18) located at the protein surface. Superposition of the coordinates of Hg-Atx1 (PDB code 1CC8) (24) and CuAtox1 (human analog of Atx1, PDB code 1FEE) (25) on the monomers in the complex ( Fig. 1C and 1D ) reveals that the peptide fold around the metal binding loop is unperturbed by TM binding, with an average rms deviation for the C α atoms of ~ 0.67 Å (Hg-Atx1) and ~ 1.3 Å (Cu-Atox1). In the structure, each Atx1 trimer coordinates four copper atoms and one TM molecule, with the stoichiometry [TM][(Cu)(CuAtx1) 3 ], which is corroborated by independent elemental analysis of the complex (23 Thus, three of the four sulfide ions in TM form a μ 3 -S bridge between the Mo atom and two tetrahedral Cu atoms, whereas each of the (Cys15)S γ atoms of three Atx1 behave as a bridging ligand between one tetrahedral and one trigonal planar copper center. In the tetrahedrally coordinated coppers, the (Cys15)S γ -Cu-S γ (Cys18) bond angles are larger (118 -125°, mean: 122°) than the (TM)S-Cu-S(TM) bond angles (99-103°, mean: 101°), consistent with a distorted tetrahedral site. The geometry at the Mo atom is only slightly distorted from tetrahedral, with (TM)(μ 3 In order to determine whether TM interaction with Atx1 inhibits its copper chaperone activity, we developed a native gel based copper transfer assay which monitors metal occupancy in a mixture of TM-Cu-Atx1 trimer and Ccc2a, the physiological partner of Atx1 ( fig. S6 ). The assay takes advantage of the fact that apo-and Cu-Atx1 are clearly distinguishable from Ccc2a and TM-Cu-Atx1 in a native agarose gel system (23) , where the protein and metal content of the bands are characterized by a variety of analytical techniques to establish the metallation state of each protein (fig. S7 to S12 and table S1). The assay was validated by a combination of protein mass spectrometry (ESI-MS) and, quantitative elemental analysis (ICP-MS) of samples extracted from gel slices, as well as by qualitative laser scanning elemental analysis (LA-ICP-MS) of the electrophoresis gel itself. Three key lanes are shown in Fig.  3A . The TM-Cu-Atx1(SeMet) migrates as a positive species containing copper and molybdenum (Lane I). Mixing of apoCcc2a and Cu-Atx1(SeMet) results in the transfer of copper from Cu-Atx1(SeMet) to Ccc2a (Lane II). The transfer of copper from Atx1(SeMet) to Ccc2a is almost completely abolished by the presence of TM (lane III). Both native Atx1 and the SeMet analog give similar results. Intriguingly, protein analysis indicates formation of a new Cu-TM protein complex, which contains the Ccc2 domain as well as TM and Cu-Atx1. The formation of this heteromeric protein complex suggests that other proteins with surface-expose MxCxxC copper binding motif will be able to form similar complexes with TM.
These results suggest a new model for how a drug can disrupt a key protein-protein interaction for metal trafficking pathways. Support for the physiological occurrence of this type of metal-protein cluster is shown in Fig. 3B (30) . The structure and biochemistry of the TM-Cu-Atx1 complex also provides chemical insights into the puzzling stoichiometry of the Cu-Mo antagonism (31) , and suggests why ternary complex formation between TM and specific Cuproteins can have pronounced physiological consequences (32) . A relatively small amount of dietary molybdenum clearly perturbs the timely dissemination of a larger pool of copper in deficiency disorders such as 'swayback' and 'teart' pasture syndrome. Our results raise the possibility that the active agent, TM, functionally suppresses copper trafficking domains that control the secretion of the active forms of copper-dependent enzymes. Finally, our results suggest that proteins involved in such metallation pathways may be targets for the development of new classes of pharmaceutical agents.
Cancer Atx1 in the TM-Cu-Atx1 complex is not disturbed by TM. The Cu coordination environment in Cu-Atx1 from TM-CuAtx1 is very similar to the one found in Cu-Atox1 (dimer) (25) , but differs with the nearly linear coordination of Hg in Hg-Atx1 (24). 
